Regulatory effect of Pseudomonas aeruginosa mannose-sensitive hemagglutinin on inflammation and immune function in percutaneous nephrolithotomy patients with upper urinary tract calculi complicated with infection.
Pseudomonas aeruginosa mannose-sensitive hemagglutinin
immunomodulator
inflammation
lymphocyte subsets
percutaneous nephrolithotomy (PCNL)
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2023
2023
Historique:
received:
07
03
2023
accepted:
20
04
2023
medline:
30
6
2023
pubmed:
28
6
2023
entrez:
28
6
2023
Statut:
epublish
Résumé
To study the effect of an injection of Pseudomonas aeruginosa mannose-sensitive hemagglutinin (PA-MSHA) on inflammation and immune function in patients with upper urinary tract calculi complicated by infection who have undergone percutaneous nephrolithotomy. We retrospectively recorded the clinical data of patients with upper urinary tract calculi complicated by infection who have undergone Percutaneous nephrolithotomy(PCNL) in the Department of Urology, 2nd Affiliation Hospital of Kunming Medical University, from March to December 2021. Clinical data include general condition, laboratory index, CT, postoperative body temperature, heart rate, respiration, SIRS, sepsis, etc. Patients were divided into treated and control groups according to whether they had received a preoperative PA-MSHA injection. The two groups were compared for indices of inflammation and complications of infection after PCNL. Pre- and post-operative lymphocyte subsets and immunoglobulin changes were compared. 115 patients were included in the study, including 43 in the treatment group and 72 in the control group. After Propensity Score Matching, 90 patients were divided into treatment (n=35) and control (n=55) groups. The postoperative inflammation index was higher in the treatment group than in the control group (P<0.05). The incidence of postoperative SIRS was higher in the treatment group than control (P<0.05). There were no cases of sepsis in either group. The double-positive T cells lymphocyte subsets were higher in the treatment group than in the control group ((P<0.05). Pre- and post-operative changes in immune function: total T lymphocyte count reduced, NK and NKT cell count increased in the control group, double-positive T cell count increased in the treatment group, IgG, IgA, IgM, complement C3 and C4 count reduced in both groups post-operatively. This study found that patients with upper urinary tract calculi and infection treated with antibiotic-based PA-MSHA before percutaneous nephrolithotomy had an increased inflammatory response after surgery, which may play a role in the prevention and treatment of sepsis. The percentage of double-positive T cells in the peripheral blood was increased after PA-MSHA treatment, which may have an immunomodulatory and protective effect in PCNL patients with stones complicated by infection.
Identifiants
pubmed: 37377966
doi: 10.3389/fimmu.2023.1181688
pmc: PMC10291127
doi:
Substances chimiques
Hemagglutinins
0
Mannose
PHA4727WTP
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1181688Informations de copyright
Copyright © 2023 Zhao, Zhang and Liu.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Biomolecules. 2021 Jul 10;11(7):
pubmed: 34356636
Crit Care. 2017 Mar 26;21(1):73
pubmed: 28342442
Nat Rev Nephrol. 2018 Feb;14(2):121-137
pubmed: 29225343
Cancer Med. 2016 Dec;5(12):3520-3531
pubmed: 27758045
J Leukoc Biol. 2015 Jan;97(1):31-8
pubmed: 25360000
Front Vet Sci. 2020 May 29;7:305
pubmed: 32548135
Clin Immunol. 2005 Jan;114(1):61-9
pubmed: 15596410
Cancer Manag Res. 2021 Jun 21;13:4873-4878
pubmed: 34188540
Crit Care. 2011;15(2):R99
pubmed: 21418617
Nat Rev Immunol. 2013 Dec;13(12):862-74
pubmed: 24232462
Sci Adv. 2023 Mar 24;9(12):eadf0567
pubmed: 36961891
Curr Opin Infect Dis. 2012 Jun;25(3):321-7
pubmed: 22421753
J Immunol. 2010 Apr 1;184(7):3768-79
pubmed: 20200277
BJU Int. 2019 Jun;123(6):1041-1047
pubmed: 30007112
Int J Mol Sci. 2017 Nov 14;18(11):
pubmed: 29135922
Indian J Med Res. 2014 Oct;140(4):513-9
pubmed: 25488445
World J Urol. 2021 Feb;39(2):501-510
pubmed: 32277278
Cancer Cell Int. 2017 Aug 17;17:76
pubmed: 28824336
JAMA. 2016 Feb 23;315(8):801-10
pubmed: 26903338
Sci Rep. 2021 Dec 8;11(1):23607
pubmed: 34880348
Intensive Care Med. 2009 Apr;35(4):678-86
pubmed: 18946659
Urol Oncol. 2014 Jan;32(1):36.e11-8
pubmed: 23948182
Rheumatology (Oxford). 2022 Mar 2;61(3):1282-1287
pubmed: 34260705
J Infect Dis. 2005 Dec 15;192(12):2074-80
pubmed: 16288370
World J Urol. 2017 Sep;35(9):1369-1379
pubmed: 28160088
Surg Today. 2010 Sep;40(9):793-808
pubmed: 20740341
J Immunol. 2002 Mar 1;168(5):2493-500
pubmed: 11859143
Urol Int. 2016;96(2):207-11
pubmed: 26745881
J Immunol. 2008 May 15;180(10):6941-6
pubmed: 18453615
World Neurosurg. 2017 Dec;108:206-215
pubmed: 28866066
J Endourol. 2016 Sep;30(9):982-6
pubmed: 27393153
Cell Biochem Biophys. 2015 Sep;73(1):245-52
pubmed: 25724441
J Trauma Acute Care Surg. 2016 Feb;80(2):335-40
pubmed: 26517783
J Med Primatol. 2019 Apr;48(2):82-89
pubmed: 30723927
Blood. 2004 Jul 15;104(2):478-86
pubmed: 15044252
Front Immunol. 2020 Aug 12;11:1786
pubmed: 32903436
Eur Urol Focus. 2019 Jan;5(1):5-9
pubmed: 30448051
Crit Care Med. 1991 Jul;19(7):874-81
pubmed: 2055075
Cochrane Database Syst Rev. 2013 Sep 16;(9):CD001090
pubmed: 24043371
Clin Vaccine Immunol. 2013 May;20(5):738-46
pubmed: 23515014
Shock. 2020 Feb;53(2):228-235
pubmed: 31935201
Mol Med Rep. 2013 Apr;7(4):1350-4
pubmed: 23440442
iScience. 2020 Sep 29;23(10):101612
pubmed: 33089101
Arch Dermatol Res. 2020 Jul;312(5):353-359
pubmed: 31797034
Intensive Care Med. 2015 Jan;41(1):131-3
pubmed: 25406407
Front Cell Infect Microbiol. 2022 Feb 24;12:834888
pubmed: 35281443
Dtsch Arztebl Int. 2015 Dec 4;112(49):837-47; quiz 848
pubmed: 26754121
Vet Immunol Immunopathol. 1999 Dec 15;72(1-2):55-66
pubmed: 10614493
PLoS One. 2015 Mar 13;10(3):e0118607
pubmed: 25768439
Int Immunopharmacol. 2013 Nov;17(3):836-42
pubmed: 24055021
PLoS One. 2012;7(10):e47209
pubmed: 23071758
Exp Biol Med (Maywood). 2020 Feb;245(3):213-220
pubmed: 31903775
Front Biosci. 2008 May 01;13:3676-84
pubmed: 18508464
Ann N Y Acad Sci. 2021 Sep;1499(1):3-17
pubmed: 32202669
Trends Immunol. 2009 Oct;30(10):475-87
pubmed: 19781994
Lancet. 2020 Jan 18;395(10219):200-211
pubmed: 31954465
Front Immunol. 2021 Feb 17;11:624279
pubmed: 33679715
Viruses. 2022 Oct 13;14(10):
pubmed: 36298798
Inflammation. 2021 Dec;44(6):2333-2345
pubmed: 34417666
PLoS One. 2013 Jul 03;8(7):e67821
pubmed: 23844100
Int Immunopharmacol. 2017 Oct;51:57-65
pubmed: 28802902
Innate Immun. 2015 Jan;21(1):55-64
pubmed: 24398860
Nature. 1997 Nov 27;390(6658):350-1
pubmed: 9389474
J Immunol. 2006 Nov 1;177(9):6540-7
pubmed: 17056586
Int Immunol. 2000 Jul;12(7):1095-103
pubmed: 10882421
Br J Pharmacol. 2018 Jul;175(14):2717-2725
pubmed: 28213891
Mol Med Rep. 2016 Dec;14(6):5369-5376
pubmed: 27779712
Nucleosides Nucleotides Nucleic Acids. 2021;40(1):16-31
pubmed: 32985358
J Biomed Res. 2022 Sep 28;:59-68
pubmed: 36625011
Antiviral Res. 2011 Jun;90(3):151-9
pubmed: 21439328
J Immunol. 2012 May 1;188(9):4289-96
pubmed: 22461689